Obesity
GLP1
+1
Oct 6, 2026
•
10 min read
23.3% Weight Loss in Type 2 Diabetes. Can Patients Stay on Treatment?
In a randomized Phase 2b trial, Lilly’s amylin-plus-tirzepatide combination showed 8.5 percentage points greater estimated weight loss than tirzepatide 15 mg. The open question is how many people can stay on it.
GLP1
+1
Oct 3, 2026
•
18 min read
Glucagon Was the Villain. Amylin Was a Footnote.
A mechanism-first deep dive into the two hormones behind the next obesity drugs: what they do in the liver and the brainstem, and what the trials can and can't confirm.
GLP1
+1
Sep 30, 2026
•
17 min read
Everyone Will Quote 28%. Read Page Four.
TRIUMPH-1 is in NEJM. The obvious findings first, then what's hiding underneath.
GLP1
+3
Sep 23, 2026
•
11 min read
Twenty-Five Trials on Binge Eating. Three Studied It.
A new meta-analysis says GLP-1s reduce binge eating. It's the most rigorous synthesis we have, and the part that answers the question rests on about 130 patients.
Obesity
+3
Sep 19, 2026
•
9 min read
I'm an Obesity Doctor. I Gained Weight on Tirzepatide.
For two years, a very low dose worked. Then stress eating broke through it. Going to 5 mg taught me something I think patients, and obesity doctors, get wrong about these drugs.
Lipedema
+3
Sep 9, 2026
•
14 min read
The Fat That Hurts Has a Name.
Lipedema often begins decades before it is diagnosed. In the largest U.S. patient registry, women first sought medical help at an average age of 39.6 and were not diagnosed until 48. This week Vineyard expanded its comprehensive obesity and cardiometabolic program with a dedicated lipedema effort led by one of the physicians who helped write the U.S. standard of care.
GLP1
+1
Sep 8, 2026
•
4 min read
Two Free Tools to Make Sense of Obesity Medications
A trial tracker and a medication comparison, free for clinicians and curious patients, plus one methods detail that changes how you read weight loss trials.
CV
+4
Aug 18, 2026
•
14 min read
It's Already on Every Panel. Nobody Reads It.
Remnant cholesterol costs nothing to calculate and predicts events when LDL no longer does. Its first real drug just proved it can prevent pancreatitis, and then failed to move plaque.
Coverage
+4
Aug 8, 2026
•
13 min read
Every First Claim Is Denied. That's the Design.
One month into the Medicare GLP-1 Bridge, the denial at the counter isn't a coverage decision — and CMS built no appeals process for the ones that are.
GLP1
+4
Aug 4, 2026
•
12 min read
Retatrutide Won Twice. The Heart Data Didn't.
TRIUMPH-2 and TRIUMPH-3 both hit — 20.8% in type 2 diabetes, 22.6% with established cardiovascular disease. Then there's the MACE table.
GLP1
+3
Jul 28, 2026
•
4 min read
The Triple Agonist, in Plain Numbers
Retatrutide is posting some of the largest weight-loss numbers the incretin class has seen. Here's what the data actually says — and the two things to watch before the headline. Free cheat sheet inside.
GLP1
+2
Jul 21, 2026
•
4 min read
I Put Twelve GLP-1 Trials on One Page
The evidence that actually holds up in 2026 — weight loss, heart, kidney, muscle, and the myths that should have died already. Free one-page reference inside.
GLP1
+2
Jul 11, 2026
•
6 min read
SPECIAL EDITION: Nobody Asked.
A new JAMA secret-shopper study bought 45 GLP-1 prescriptions online. Most arrived in a day. Some in under 5 minutes. Almost none asked the questions that keep patients safe. I have watched this happen from the inside, and I know exactly why.
GLP1
+1
Jul 7, 2026
•
3 min read
I Built a Live Index of Every Obesity Drug Trial
The pipeline moves faster than any newsletter can. So I stopped trying to summarize it and built something that updates itself.
GLP1
+2
Jul 4, 2026
•
11 min read
Obesity Medicine Stopped Being a Horse Race
Nine drugs, four receptors, and two new pills into 2026, the field is quietly reorganizing around a better question. Not how much weight. Which disease.
GLP1
+2
Jun 23, 2026
•
8 min read
Medicare Will Pay for Wegovy Now. Here's the Catch.
Starting July 1, eligible Medicare patients get Wegovy, Zepbound, or the new pill Foundayo for $50 a month. The program is real. It's transformative. And almost everything you've read about it is slightly wrong.
Obesity
+1
Jun 19, 2026
•
9 min read
Obesity Care: I Was Wrong
I argued for fixing the system from the inside. The evidence changed my mind.
GLP1
+2
Jun 16, 2026
•
9 min read
Glucagon Doesn't Win the Scale. It Wins the Liver.
Survodutide and pemvidutide keep landing below 20% on body weight — while clearing liver fat at rates no pure GLP-1 can touch. A dispatch on the ADA 2026 readouts, and the case for grading incretins on the right organ.
GLP1
+2
May 19, 2026
•
13 min read
ECO 2026: The Maintenance Era Begins.
Istanbul gave us the answers we have been waiting for. Obesity is now being treated like every other chronic disease — and the data is on the right side of history.
